US Stock MarketDetailed Quotes

CMMB Chemomab Therapeutics

Watchlist
  • 1.160
  • +0.040+3.57%
Close Jul 22 16:00 ET
16.49MMarket Cap-753P/E (TTM)

Chemomab Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
(Q2)Jun 30, 2022
(Q1)Mar 31, 2022
(FY)Dec 31, 2021
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
-55.27%4.05M
-10.77%25.46M
31.04%8.2M
70.09%9.05M
130.72%28.53M
8.64M
187.69%8.32M
127.17%6.25M
213.13%5.32M
107.08%12.37M
Selling and administrative expenses
-56.71%936K
-38.75%7.08M
-4.94%3.18M
-16.04%2.16M
91.55%11.56M
--2.75M
106.13%2.89M
130.98%3.34M
375.09%2.58M
368.40%6.03M
-General and administrative expense
-56.71%936K
-38.75%7.08M
-4.94%3.18M
-16.04%2.16M
91.55%11.56M
--2.75M
106.13%2.89M
130.98%3.34M
375.09%2.58M
368.40%6.03M
Research and development costs
-54.81%3.11M
8.27%18.38M
72.27%5.02M
150.89%6.89M
168.03%16.98M
--5.9M
264.69%5.42M
122.95%2.91M
137.25%2.75M
35.23%6.33M
Operating profit
55.27%-4.05M
10.77%-25.46M
-31.04%-8.2M
-70.09%-9.05M
-130.72%-28.53M
-8.64M
-187.69%-8.32M
-127.17%-6.25M
-213.13%-5.32M
-107.08%-12.37M
Net non-operating interest income expense
-43.22%180K
250.71%1.24M
153.96%259K
46.76%317K
418.02%353K
380K
407.79%237K
-2,723.53%-480K
4,420.00%216K
-628.57%-111K
Total other finance cost
43.22%-180K
-250.71%-1.24M
-153.96%-259K
-46.76%-317K
-418.02%-353K
---380K
-407.79%-237K
2,723.53%480K
-4,420.00%-216K
628.57%111K
Other net income (expense)
Income before tax
55.70%-3.87M
14.05%-24.22M
-17.85%-7.94M
-71.08%-8.73M
-125.84%-28.18M
-8.26M
-172.24%-8.08M
-143.10%-6.73M
-199.53%-5.1M
-109.68%-12.48M
Income tax
0
0
106.25%34K
21K
-534K
10K
0
-544K
0
0
Net income
55.81%-3.87M
12.39%-24.22M
-28.76%-7.97M
-71.49%-8.75M
-121.56%-27.65M
-8.27M
-172.24%-8.08M
-123.47%-6.19M
-199.53%-5.1M
-109.68%-12.48M
Net income continuous Operations
55.81%-3.87M
12.39%-24.22M
-28.76%-7.97M
-71.49%-8.75M
-121.56%-27.65M
---8.27M
-172.24%-8.08M
-123.47%-6.19M
-199.53%-5.1M
-109.68%-12.48M
Minority interest income
Net income attributable to the parent company
55.81%-3.87M
12.39%-24.22M
-28.76%-7.97M
-71.49%-8.75M
-121.56%-27.65M
-8.27M
-172.24%-8.08M
-123.47%-6.19M
-199.53%-5.1M
-109.68%-12.48M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
55.81%-3.87M
12.39%-24.22M
-28.76%-7.97M
-71.49%-8.75M
-121.56%-27.65M
-8.27M
-172.24%-8.08M
-123.47%-6.19M
-199.53%-5.1M
-109.68%-12.48M
Basic earnings per share
65.00%-0.28
14.88%-2.06
-33.33%-0.72
-81.82%-0.8
-101.67%-2.42
-0.72
-169.23%-0.7
-107.69%-0.54
-100.00%-0.44
-121.87%-1.2
Diluted earnings per share
65.00%-0.28
14.88%-2.06
-33.33%-0.72
-81.82%-0.8
-101.67%-2.42
-0.72
-169.23%-0.7
-107.69%-0.54
-100.00%-0.44
-121.87%-1.2
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
--
Unqualified Opinion
--
--
--
--
--
(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022(Q2)Jun 30, 2022(Q1)Mar 31, 2022(FY)Dec 31, 2021
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense -55.27%4.05M-10.77%25.46M31.04%8.2M70.09%9.05M130.72%28.53M8.64M187.69%8.32M127.17%6.25M213.13%5.32M107.08%12.37M
Selling and administrative expenses -56.71%936K-38.75%7.08M-4.94%3.18M-16.04%2.16M91.55%11.56M--2.75M106.13%2.89M130.98%3.34M375.09%2.58M368.40%6.03M
-General and administrative expense -56.71%936K-38.75%7.08M-4.94%3.18M-16.04%2.16M91.55%11.56M--2.75M106.13%2.89M130.98%3.34M375.09%2.58M368.40%6.03M
Research and development costs -54.81%3.11M8.27%18.38M72.27%5.02M150.89%6.89M168.03%16.98M--5.9M264.69%5.42M122.95%2.91M137.25%2.75M35.23%6.33M
Operating profit 55.27%-4.05M10.77%-25.46M-31.04%-8.2M-70.09%-9.05M-130.72%-28.53M-8.64M-187.69%-8.32M-127.17%-6.25M-213.13%-5.32M-107.08%-12.37M
Net non-operating interest income expense -43.22%180K250.71%1.24M153.96%259K46.76%317K418.02%353K380K407.79%237K-2,723.53%-480K4,420.00%216K-628.57%-111K
Total other finance cost 43.22%-180K-250.71%-1.24M-153.96%-259K-46.76%-317K-418.02%-353K---380K-407.79%-237K2,723.53%480K-4,420.00%-216K628.57%111K
Other net income (expense)
Income before tax 55.70%-3.87M14.05%-24.22M-17.85%-7.94M-71.08%-8.73M-125.84%-28.18M-8.26M-172.24%-8.08M-143.10%-6.73M-199.53%-5.1M-109.68%-12.48M
Income tax 00106.25%34K21K-534K10K0-544K00
Net income 55.81%-3.87M12.39%-24.22M-28.76%-7.97M-71.49%-8.75M-121.56%-27.65M-8.27M-172.24%-8.08M-123.47%-6.19M-199.53%-5.1M-109.68%-12.48M
Net income continuous Operations 55.81%-3.87M12.39%-24.22M-28.76%-7.97M-71.49%-8.75M-121.56%-27.65M---8.27M-172.24%-8.08M-123.47%-6.19M-199.53%-5.1M-109.68%-12.48M
Minority interest income
Net income attributable to the parent company 55.81%-3.87M12.39%-24.22M-28.76%-7.97M-71.49%-8.75M-121.56%-27.65M-8.27M-172.24%-8.08M-123.47%-6.19M-199.53%-5.1M-109.68%-12.48M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 55.81%-3.87M12.39%-24.22M-28.76%-7.97M-71.49%-8.75M-121.56%-27.65M-8.27M-172.24%-8.08M-123.47%-6.19M-199.53%-5.1M-109.68%-12.48M
Basic earnings per share 65.00%-0.2814.88%-2.06-33.33%-0.72-81.82%-0.8-101.67%-2.42-0.72-169.23%-0.7-107.69%-0.54-100.00%-0.44-121.87%-1.2
Diluted earnings per share 65.00%-0.2814.88%-2.06-33.33%-0.72-81.82%-0.8-101.67%-2.42-0.72-169.23%-0.7-107.69%-0.54-100.00%-0.44-121.87%-1.2
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions --------Unqualified Opinion----------

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg